Belgium, September 12, 2022 – Synergia Medical, a preclinical medical device company specializing in the development of NAO.VNS (Vagus Nerve Stimulation), has announced the successful completion of a €9 million Series B funding round. This significant financial achievement enables the company to prepare for First-In-Human clinical trials planned for 2023 and the submission of an Investigational Device Exemption (IDE) to the FDA in the USA. The IDE allows the investigational device to be used in clinical studies to collect safety and efficacy data.
The funding round saw participation from a mix of historical private shareholders, Newton Biocapital, public investors (SFPI, SRIW Life Sciences, Investsud), the Walloon region, and was joined by the institutional investor TheClubDeal, which specializes in the life sciences, technology, and Smart Living sectors.
Attila Borbath, CEO & Co-founder of Synergia Medical, expressed his gratitude towards the investors for their confidence and support, highlighting the importance of this funding in advancing their clinical trials and regulatory milestones. Sophie Baratte, Chairman of the Board of Directors, emphasized the company's commitment to improving the lives of epilepsy patients through innovative Vagus Nerve Stimulation treatment.
Jean-Marc Legrand, CEO of TheClubDeal, praised Synergia Medical for its breakthrough project and the capable team behind it, noting the company's solid patents as a key factor in their investment decision.
Since its inception in 2016, Synergia Medical has raised over €26 million. The company employs 25 staff members, focusing on pre-clinical studies, R&D, and expertise in quality and regulatory affairs. It is supported by a business-oriented Board of Directors with extensive experience in the health sector and a Scientific Advisory Board comprising world-renowned experts in neural stimulation and epilepsy.
